Curis, Inc. has initiated a new strategic focus on seeking to develop later-stage drug development programs and to de-emphasize its earlier-stage discovery research. This new direction represents an expansion of Curis’ continuing strategy to mitigate risk by seeking to both create and acquire a broad portfolio of later-developmental stage assets and maximize the company’s capacity and competencies in drug development. Curis will also continue to evaluate in-licensing opportunities to...